What diversity means in medtech

Since the first days of the new Trump administration, the White House has handed down orders to ban work focused on diversity, equity and inclusion (DEI) across the federal government. Some in the private sector—both inside and outside of healthcare—have followed the same path, eliminating DEI officer positions and ending initiatives that in some cases have been tied to millions of dollars in research funding. What does the field—and, ultimately, the patient—stand to lose from this effort?

In this week’s episode of The Top Line, we hear from Nada Hanafi, co-founder of MedTech Color, a professional network aimed at building and supporting diverse leadership in the industry. Hanafi joins Fierce Medtech’s Conor Hale to discuss how studying diversity in a healthcare context has become integral to developing new medical breakthroughs and realizing the promise of precision medicine.

To learn more about the topics in this episode:

• FDA issues draft guidance on ensuring pulse oximeter accuracy across skin tones 

• How Trump's DEI executive orders could impact healthcare 

• After White House transition, FDA’s diversity guidance for clinical trials no longer available 

• As Trump targets DEI practices, 4 pharmas reaffirm commitment to diversifying clinical trials 

• Amid Trump's push to abolish DEI, Roche and Novartis adjust hiring initiatives: reports 

See omnystudio.com/listener for privacy information.